Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

April 2, 2020

Study Completion Date

April 2, 2020

Conditions

NAFLD

Interventions

DRUG

somatropin

Norditropin (growth hormone) given by injection using a pen-device

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT02726542 - Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents | Biotech Hunter | Biotech Hunter